Lung Squamous Cell Carcinoma with EML4-ALK Fusion and TP53 Co-mutation
Treated with Ensartinib: A Case Report and Literature Review.
10.3779/j.issn.1009-3419.2023.106.03
- Author:
Donglai LV
1
;
Chunwei XU
2
;
Chong WANG
1
;
Qiuju SANG
1
Author Information
1. Department of Medical Oncology, 901 Hospital of Joint Logistics Support Force of People Liberation Army, Hefei 230031, China.
2. Department of Respiratory and Critical Care Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China.
- Publication Type:Journal Article
- Keywords:
ALK fusion gene;
Ensartinib;
Lorlatinib;
Lung neoplasms;
Tp53
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/drug therapy*;
Lung Neoplasms/pathology*;
Anaplastic Lymphoma Kinase/metabolism*;
Carcinoma, Squamous Cell/genetics*;
Mutation;
Cytoskeletal Proteins/genetics*;
Lung/pathology*;
Oncogene Proteins, Fusion/genetics*;
Protein Kinase Inhibitors/therapeutic use*;
Tumor Suppressor Protein p53/genetics*
- From:
Chinese Journal of Lung Cancer
2023;26(1):78-82
- CountryChina
- Language:Chinese
-
Abstract:
Lung squamous cell carcinoma (LSCC) accounts for approximately 30% of non-small cell lung cancer (NSCLC) cases and is the second most common histological type of lung cancer. Anaplastic lymphoma kinase (ALK)-positive NSCLC accounts for only 2%-5% of all NSCLC cases, and is almost exclusively detected in patients with lung adenocarcinoma. Thus, ALK testing is not routinely performed in the LSCC population, and the efficacy of such treatment for ALK-rearranged LSCC remains unknown. Echinoderm microtubule associated protein like 4 (EML4)-ALK (V1) and TP53 co-mutations were identified by next generation sequencing (NGS) in this patient with advanced LSCC. On December 3, 2020, Ensatinib was taken orally and the efficacy was evaluated as partial response (PR). The progression-free survival (PFS) was 19 months. When the disease progressed, the medication was changed to Loratinib. To our knowledge, Enshatinib created the longest PFS of ALK-mutant LSCC patients treated with targeted therapy since literature review. Herein, we described one case treated by Enshatinib involving a patient with both EML4-ALK and TP53 positive LSCC, and the relevant literatures were reviewed for discussing the treatment of this rare disease.
.
